Add as a preferred source on GoogleLineage Cell Therapeutics Adds HUNT1, Projects Funding Into Q2 2028
The company reported $45.2 million in cash, cash equivalents and marketable securities. HUNT1 is an enrolling Phase Ib/IIa program for Huntington’s disease.
Lineage Cell Therapeutics projects that its available funding will cover operations into the second quarter of 2028, while the company adds an enrolling Huntington’s disease program to its clinical pipeline.
The company reported $45.2 million in cash, cash equivalents and marketable securities.
The new program, HUNT1, was formerly known as hNSC-01 and came to Lineage through its acquisition of NeuroAirmid Therapeutics. It is a Phase Ib/IIa study for Huntington’s disease and brings the company’s clinical-stage asset count to three.
The study is enrolling.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.